Fed. Circ. Upholds Invalidity Of J&J Concerta Patent
The U.S. Court of Appeals for the Federal Circuit ruled Monday that the patent was invalid for lack of enablement, affirming the U.S. District Court for the District of Delaware's March 2009 opinion in favor of Andrx.
U.S. Patent Number 6,919,373 claims methods for treating ADHD through a methylphenidate drug dosage...
To view the full article, register now.